Stefania Salvagni

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath et al. · The Lancet Oncology · 2012 · 549 citations

Second-line Treatment, Placebo-controlled Phase 2, Oncology +11

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Neal Ready, Patrick A. Ott, Matthew D. Hellmann et al. · Journal of Thoracic Oncology · 2019 · 319 citations · Full text

Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Luca Gianni, Anna Lladó, Giulia Bianchi et al. · Journal of Clinical Oncology · 2010 · 266 citations · Full text

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Javier Cortés, P. Fumoleau, Giulia Bianchi et al. · Journal of Clinical Oncology · 2012 · 245 citations · Full text

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

Tiziana Pressiani, C. Boni, Lorenza Rimassa et al. · Annals of Oncology · 2012 · 149 citations · Full text

Hepatology, Medicine, Liver Physiology +12